Sawai Pharmaceutical Co., Ltd.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Sawai Pharmaceutical Co., Ltd.
Teva announced the appointment of former Sandoz CEO Richard Francis as its next leader as Kare Schultz steps down.
Sawai’s Q1 momentum spread into its overall first half financial results, with setbacks and risks in its dominant Japanese business and greener shoots for its formerly spluttering Upsher-Smith operation in the US.
Sawai’s Upsher-Smith business in the US has announced a pair of deals that will see the firm expand an existing partnership with Appco for a “near-term generic product opportunity” as well as divesting two “dormant” ANDAs in favor of a focus on more immediate assets.
Cidara gets $30m up front for US rights to the weekly echinocandin candidate for candidemia and invasive candidiasis. Takeda walks away from oncolytic virus candidate licensed from Turnstone.
- Generic Drugs
- Other Names / Subsidiaries
- Cambridge Biotechnology Ltd (CBT)
- Minster Pharmaceuticals
- Proximagen Group
- Upsher-Smith Laboratories Inc.
- Medisa Shinyaku Inc. and Kaken Shoyaku Inc.